Mitochondrial DNA mutations in the haematopoietic system Leukemia (2004) currently known about the role of mitochondrial DNA (mtDNA) mutations in the haematopoietic system. In addition to his previous work on myelodysplastic syndromes (MDS), 3 our recent studies 2 show that somatic mtDNA mutations are present in some patients with leukaemia. What are the wider implications of this observation?
One interpretation of our data is that clonal mtDNA mutations are present in haematopoietic stem cells. These mutations presumably accumulate with age, a phenomenon previously described in many postmitotic and dividing cells, 4 and that we have also recently observed in human colonic crypt stem cells. 5 What is still uncertain is whether the mtDNA mutations we have Time-point analysis for tax mRNA expression by RQ-PCR. The tax expression was serially quantified (closed circle) during the course of all-SCT. Open squares indicate hematological relapse. HUT102 cells were used as a positive control and the tax expression level in this cell line was set as 1. Dx, diagnosis.
observed in patients with leukaemia have any effect on ATP production and consequently stem cell function. There is the possibility that these mtDNA mutations have a subtle effect on mitochondrial function and this increases the risk of a stem cell becoming malignant. While this view is discussed by Gattermann, 1 the only way to test this hypothesis is to directly measure the mutation load (and spectrum) in haematological stem cells from normal adults and to directly compare with the changes seen in leukaemia.
The discovery of pathogenic mtDNA mutations in MDS patients is intriguing. In Pearson's syndrome, sideroblastic anaemia is prominent and thus it is accepted that a respiratory chain abnormality as a consequence of mtDNA mutation (in this case a single, large-scale mtDNA deletion) can affect blood cell maturation. However, in patients with MDS who have a pathogenic mtDNA mutation, the mutation must be acquired and clonally expand through the haematopoeitic tissues. This would seem remarkable for a cell that has a severely compromised respiratory chain function and is in stark contrast to the observed situation in inherited mtDNA abnormalities in which the mutation is lost in blood. 6 The effect of the respiratory chain defect in MDS therefore seems to be more severe on cell maturation than replication. Do our observations have other important implications? As highlighted by Gattermann, 1 the mitochondrial genome is present in multiple copies in individual cells, thus permitting extensive molecular genetic studies at the level of the single cell. 7, 8 On account of this high copy compared to nuclear gene targets, we believe that somatic mtDNA mutations may prove useful in the detection of malignant leukaemic clones and therefore as markers of disease activity. 2 While we do not directly compare mtDNA markers with nuclear markers of mimimal residual disease in our manuscript, such a study may prove important in the future. A much more long-term goal is also to consider the presence of a somatic, clonal mtDNA mutation as a potential target for treatment. The work of our own group focuses predominantly on the detection and characterisation of inherited mtDNA mutations, a common genetic cause of neurological and neuromuscular conditions that affect at least 1 in 10 000 of the population. 9 In spite of our extensive understanding of the pathogenesis of many of these mtDNA mutations, at present there is little we can offer our patients in terms of treatment. Developing molecules and drugs that can specifically target mutated mtDNA is a priority for patients with mtDNA disease, 10 but any such approach, if successful, may also be of value on treating leukaemia or other malignancies in which there are clonal mtDNA mutations.
In conclusion, we believe our studies have shown convincingly that acquired mtDNA mutations occur in leukaemia. Our paper documents the phenomenology, but further studies are now required to elucidate the significance of these sequence changes in the development of leukaemia. 
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